Loading company…
NuCana develops cancer therapies using its proprietary ProTide technology.
Founded in 2008 and based in Edinburgh, UK, NuCana develops cancer therapies using its ProTide technology to modify existing drugs. The company is advancing treatments for several cancer types. In September 2017, it raised USD 100 mn through an IPO to support research, development, and clinical trials. Hugh Griffith is its CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at NuCana BioMed Limited? This is my company